We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Takeda Acquires U.S. Biologics Manufacturing Facility
News

Takeda Acquires U.S. Biologics Manufacturing Facility

Takeda Acquires U.S. Biologics Manufacturing Facility
News

Takeda Acquires U.S. Biologics Manufacturing Facility

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Takeda Acquires U.S. Biologics Manufacturing Facility"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Takeda intends to use the facility primarily for the manufacture of Entyvio®( vedolizumab) and other biologic products, allowing the company to maximize global efficiencies and further enhance the product’s supply chain flexibility.

“Takeda’s focus is providing patients access to quality therapies,” said Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda. “Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”

The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.

Advertisement